"Genes, BRCA1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.
| Descriptor ID |
D019398
|
| MeSH Number(s) |
G05.360.340.024.340.375.249.100 G05.360.340.024.340.415.400.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Genes, BRCA1".
Below are MeSH descriptors whose meaning is more specific than "Genes, BRCA1".
This graph shows the total number of publications written about "Genes, BRCA1" by people in this website by year, and whether "Genes, BRCA1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 2 | 2 | 4 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 2 | 4 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genes, BRCA1" by people in Profiles.
-
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. Br J Cancer. 2024 Nov; 131(9):1400-1414.
-
Hereditary Breast Cancer: BRCA Mutations and Beyond. Radiol Clin North Am. 2024 Jul; 62(4):627-642.
-
TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol. Int J Gynecol Cancer. 2023 06 05; 33(6):982-987.
-
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the?USA with ovarian cancer from 2011 to 2018. Future Oncol. 2021 Nov; 17(32):4263-4274.
-
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. Eur J Cancer. 2021 09; 154:35-45.
-
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.
-
Hereditary ovarian tumour syndromes: current update on genetics and imaging. Clin Radiol. 2021 Apr; 76(4):313.e15-313.e26.
-
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 01 06; 19(1):77-102.